CEO Joaquin Duato presented a strong outlook for Johnson & Johnson's (J&J) revenue growth in 2026, with particular optimism about oncology. Duato identified six major growth drivers, three in pharma (oncology, immunology, and neuroscience) and three in medtech (surgery, cardiovascular, and vision). These drivers position J&J to reach 5-7% annual growth and even exceeding that by the end of the decade, with potential to reach double digit growth in the 2030s. Oncology is set to play a major role in J&J’s op ...